197 related articles for article (PubMed ID: 10720512)
61. The antiviral activity, mechanism of action, clinical significance and resistance of abacavir in the treatment of pediatric AIDS.
Melroy J; Nair V
Curr Pharm Des; 2005; 11(29):3847-52. PubMed ID: 16305515
[TBL] [Abstract][Full Text] [Related]
62. Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity.
Diallo K; Marchand B; Wei X; Cellai L; Götte M; Wainberg MA
J Virol; 2003 Aug; 77(16):8621-32. PubMed ID: 12885880
[TBL] [Abstract][Full Text] [Related]
63. Mechanisms involved in the selection of HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with nucleoside analogue therapy failure.
Betancor G; Puertas MC; Nevot M; Garriga C; Martínez MA; Martinez-Picado J; Menéndez-Arias L
Antimicrob Agents Chemother; 2010 Nov; 54(11):4799-811. PubMed ID: 20733040
[TBL] [Abstract][Full Text] [Related]
64. Effect of co-formulated zidovudine, lamivudine and abacavir (Trizivir) on antiretroviral-naive patients presenting with advanced HIV-1 infection.
Seaton RA; Fox R; Bodasing N; Peters SE; Gourlay Y
AIDS; 2003 Feb; 17(3):445-7. PubMed ID: 12556701
[No Abstract] [Full Text] [Related]
65. AIDS drug in halted trial less effective as monotherapy.
AIDS Read; 2003 Apr; 13(4):159. PubMed ID: 12741364
[No Abstract] [Full Text] [Related]
66. Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy.
Precious HM; Günthard HF; Wong JK; D'Aquila RT; Johnson VA; Kuritzkes DR; Richman DD; Leigh Brown AJ
AIDS; 2000 Jan; 14(1):31-6. PubMed ID: 10714565
[TBL] [Abstract][Full Text] [Related]
67. Where now for Trizivir? Role of the triple-NRTI pill post-ACTG 5095.
Moyle GJ
AIDS Read; 2003 May; 13(5):223-4, 227, 244. PubMed ID: 12800825
[No Abstract] [Full Text] [Related]
68. Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy.
Pellegrin I; Caumont A; Garrigue I; Merel P; Schrive MH; Fleury H; Dupon M; Pellegrin JL; Ragnaud JM
J Infect Dis; 2003 Jan; 187(1):38-46. PubMed ID: 12508144
[TBL] [Abstract][Full Text] [Related]
69. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults.
Kumar PN; Sweet DE; McDowell JA; Symonds W; Lou Y; Hetherington S; LaFon S
Antimicrob Agents Chemother; 1999 Mar; 43(3):603-8. PubMed ID: 10049274
[TBL] [Abstract][Full Text] [Related]
70. Transport characteristics of the anti-human immunodeficiency virus nucleoside analog, abacavir, into brain and cerebrospinal fluid.
Thomas SA; Bye A; Segal MB
J Pharmacol Exp Ther; 2001 Sep; 298(3):947-53. PubMed ID: 11504789
[TBL] [Abstract][Full Text] [Related]
71. [Prospects in the treatment of AIDS. II. AZT and related compounds; practical conclusions].
Grieb P
Pol Arch Med Wewn; 1992; 87(4-5):316-23. PubMed ID: 1381825
[No Abstract] [Full Text] [Related]
72. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study.
McDowell JA; Chittick GE; Ravitch JR; Polk RE; Kerkering TM; Stein DS
Antimicrob Agents Chemother; 1999 Dec; 43(12):2855-61. PubMed ID: 10582871
[TBL] [Abstract][Full Text] [Related]
73. Trizivir on the market.
Kerr C
Trends Microbiol; 2001 Jan; 9(1):13. PubMed ID: 11166234
[No Abstract] [Full Text] [Related]
74. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.
Daluge SM; Good SS; Faletto MB; Miller WH; St Clair MH; Boone LR; Tisdale M; Parry NR; Reardon JE; Dornsife RE; Averett DR; Krenitsky TA
Antimicrob Agents Chemother; 1997 May; 41(5):1082-93. PubMed ID: 9145874
[TBL] [Abstract][Full Text] [Related]
75. The abacavir hypersensitivity reaction: a review.
Clay PG
Clin Ther; 2002 Oct; 24(10):1502-14. PubMed ID: 12462283
[TBL] [Abstract][Full Text] [Related]
76. Clinically relevant interpretation of genotype for resistance to abacavir.
Brun-Vézinet F; Descamps D; Ruffault A; Masquelier B; Calvez V; Peytavin G; Telles F; Morand-Joubert L; Meynard JL; Vray M; Costagliola D;
AIDS; 2003 Aug; 17(12):1795-802. PubMed ID: 12891065
[TBL] [Abstract][Full Text] [Related]
77. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.
Hughes W; McDowell JA; Shenep J; Flynn P; Kline MW; Yogev R; Symonds W; Lou Y; Hetherington S
Antimicrob Agents Chemother; 1999 Mar; 43(3):609-15. PubMed ID: 10049275
[TBL] [Abstract][Full Text] [Related]
78. Mutations M184V and Y115F in HIV-1 reverse transcriptase discriminate against "nucleotide-competing reverse transcriptase inhibitors".
Ehteshami M; Scarth BJ; Tchesnokov EP; Dash C; Le Grice SF; Hallenberger S; Jochmans D; Götte M
J Biol Chem; 2008 Oct; 283(44):29904-11. PubMed ID: 18728003
[TBL] [Abstract][Full Text] [Related]
79. Comparison of culture- and non-culture-based methods for quantification of viral load and resistance to antiretroviral drugs in patients given zidovudine monotherapy.
Tedder RS; Kaye S; Loveday C; Weller IV; Jeffries D; Norman J; Weber J; Bourelly M; Foxall R; Babiker A; Darbyshire JH
J Clin Microbiol; 1998 Apr; 36(4):1056-63. PubMed ID: 9542937
[TBL] [Abstract][Full Text] [Related]
80. Abacavir for children and adults.
Treat Rev; 1997 Nov; (No 26-27):10-1. PubMed ID: 11364930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
